Interaction of Berberine derivative with protein POT1 affect telomere function in cancer cells

Biochemical and Biophysical Research Communications

Volumn 419, Issue 3, 2012, Pages 567-572

  Xiao, Nannan ^a   Chen, Siqi ^a   Ma, Yan ^a   Qiu, Jun ^a   Tan, Jia Heng ^a   Ou, Tian Miao ^a   Gu, Lian Quan ^a   Huang, Zhi Shu ^a   Li, Ding ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Berberine derivative; Cancer; G quadruplex; POT1; Telomere

Indexed keywords

ANTINEOPLASTIC AGENT; BERBERINE DERIVATIVE; GUANINE QUADRUPLEX; LIGAND; PROTEIN POT1; SINGLE STRANDED DNA; SYSU 00692; TELOMERASE; TELOMERE BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL DESTRUCTION; CANCER THERAPY; CELL PROLIFERATION; CELL STRAIN HL 60; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOTOXICITY; DIMERIZATION; DNA STRUCTURE; DRUG DESIGN; DRUG SCREENING; DRUG TARGETING; ENERGY TRANSFER; ENZYME INHIBITION; ESCHERICHIA COLI; FLUORESCENCE RESONANCE ENERGY TRANSFER; GEL MOBILITY SHIFT ASSAY; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN INTERACTION; PROTEIN PURIFICATION; TELOMERE; TELOMERE SHORTENING;

ANTINEOPLASTIC AGENTS; BERBERINE; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CLONING, MOLECULAR; DNA, SINGLE-STRANDED; DRUG DESIGN; FLUORESCENCE RESONANCE ENERGY TRANSFER; G-QUADRUPLEXES; HUMANS; LIGANDS; NEOPLASMS; RECOMBINANT PROTEINS; TELOMERASE; TELOMERE; TELOMERE-BINDING PROTEINS;

ESCHERICHIA COLI;

EID: 84862805273     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.02.063     Document Type: Article

References (39)

1. Blackburn E.H. Switching and signaling at the telomere. Cell 2001, 106:661-673.
2. Blasco M.A. Telomeres and human disease: ageing, cancer and beyond. Nat. Rev. Genet. 2005, 6:611-622.
3. Kim Sh S.H., Kaminker P., Campisi J. Telomeres, aging and cancer: in search of a happy ending. Oncogene 2002, 21:503-511.
4. Deng Y., Chan S.S., Chang S. Telomere dysfunction and tumour suppression: the senescence connection. Nat. Rev. Cancer 2008, 8:450-458.
5. Greider C.W., Blackburn E.H. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985, 43:405-413.
6. Morin G.B. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 1989, 59:521-529.
7. Masutomi K., Yu E.Y., Khurts S., Ben-Porath I., Currier J.L., Metz G.B., Brooks M.W., Kaneko S., Murakami S., DeCaprio J.A., Weinberg R.A., Stewart S.A., Hahn W.C. Telomerase maintains telomere structure in normal human cells. Cell 2003, 114:241-253.
8. Masutomi K., Possemato R., Wong J.M., Currier J.L., Tothova Z., Manola J.B., Ganesan S., Lansdorp P.M., Collins K., Hahn W.C. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc. Natl. Acad. Sci. USA 2005, 102:8222-8227.
9. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., Coviello G.M., Wright W.E., Weinrich S.L., Shay J.W. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015.
10. Hiyama E., Hiyama K. Telomere and telomerase in stem cells. Br. J. Cancer 2007, 96:1020-1024.
11. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Gene Dev. 2005, 19:2100-2110.
12. De Cian A., Lacroix L., Douarre C., Temime-Smaali N., Trentesaux C., Riou J.F., Mergny J.L. Targeting telomeres and telomerase. Biochimie 2008, 90:131-155.
13. Simonsson T. G-quadruplex DNA structures - variations on a theme. Biol. Chem. 2001, 382:621-628.
14. Ou T.M., Lu Y.J., Tan J.H., Huang Z.S., Wong K.Y., Gu L.Q. G-quadruplexes: targets in anticancer drug design. ChemMedChem 2008, 3:690-713.
15. Baumann P., Podell E., Cech T.R. Human Pot1 (protection of telomeres) protein: cytolocalization, gene structure, and alternative splicing. Mol. Cell. Biol. 2002, 22:8079-8087.
16. Greider C.W. Telomeres do d-loop-t-loop. Cell 1999, 97:419-422.
17. Hockemeyer D., Sfeir A.J., Shay J.W., Wright W.E., de Lange T. POT1 protects telomeres from a transient DNA damage response and determines how human chromosomes end. EMBO J. 2005, 24:2667-2678.
18. Baumann P., Cech T.R. Pot1, the putative telomere end-binding protein in fission yeast and humans. Science 2001, 292:1171-1175.
19. Veldman T., Etheridge K.T., Counter C.M. Loss of hPot1 function leads to telomere instability and a cut-like phenotype. Curr. Biol. 2004, 14:2264-2270.
20. Zaug A.J., Podell E.R., Cech T.R. Human POT1 disrupts telomeric G-quadruplexes allowing telomerase extension in vitro. Proc. Natl. Acad. Sci. USA 2005, 102:10864-10869.
21. Gomez D., Wenner T., Brassart B., Douarre C., O'Donohue M.F., El Khoury V., Shin-Ya K., Morjani H., Trentesaux C., Riou J.F. Telomestatin-induced telomere uncapping is modulated by POT1 through G-overhang extension in HT1080 human tumor cells. J. Biol. Chem. 2006, 281:38721-38729.
22. Rodriguez R., Muller S., Yeoman J.A., Trentesaux C., Riou J.F., Balasubramanian S. A novel small molecule that alters shelterin integrity and triggers a DNA-damage response at telomeres. J. Am. Chem. Soc. 2008, 130:15758-15759.
23. Ma Y., Ou T.M., Hou J.Q., Lu Y.J., Tan J.H., Gu L.Q., Huang Z.S. 9-N-Substituted berberine derivatives: stabilization of G-quadruplex DNA and down-regulation of oncogene c-myc. Bioorg. Med. Chem. 2008, 16:7582-7591.
24. Bilsland A.E., Cairney C.J., Keith W.N. Targeting the telomere and shelterin complex for cancer therapy: current views and future perspectives. J. Cell Mol. Med. 2011, 15:179-186.
25. Gowan S.M., Heald R., Stevens M.F.G., Kelland L.R. Potent inhibition of telomerase by small-molecule pentacyclic acridines capable of interacting with G-quadruplexes. Mol. Pharmacol. 2001, 60:981-988.
26. Leonetti C., Scarsella M., Riggio G., Rizzo A., Salvati E., D'Incalci M., Staszewsky L., Frapolli R., Stevens M.F., Stoppacciaro A., Mottolese M., Antoniani B., Gilson E., Zupi G., Biroccio A. G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors. Clin. Cancer Res. 2008, 14:7284-7291.
27. Salvati E., Leonetti C., Rizzo A., Scarsella M., Mottolese M., Galati R., Sperduti I., Stevens M.F.G., D'Incalci M., Blasco M., Chiorino G., Bauwens S., Horard B., Gilson E., Stoppacciaro A., Zupi G., Biroccio A. Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. J. Clin. Invest. 2007, 117:3236-3247.
28. Burger A.M., Dai F.P., Schultes C.M., Reszka A.P., Moore M.J., Double J.A., Neidle S. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. Cancer Res. 2005, 65:1489-1496.
29. Gowan S.M., Harrison J.R., Patterson L., Valenti M., Read M.A., Neidle S., Kelland L.R. A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. Mol. Pharmacol. 2002, 61:1154-1162.
30. Taetz S., Murdter T.E., Zapp J., Boettcher S., Baldes C., Kleideiter E., Piotrowska K., Schaefer U.F., Kotz U., Lehr C.M. Decomposition of the telomere-targeting agent BRACO19 in physiological media results in products with decreased inhibitory potential. Int. J. Pharmaceut. 2008, 357:6-14.
31. Folini M., Gandellini P., Zaffaroni N. Targeting the telosome: therapeutic implications. BBA-Mol. Basis Dis. 2009, 1792:309-316.
32. Loayza D., Parsons H., Donigian J., Hoke K., de Lange T. DNA binding features of human POT1: a nonamer 5'-TAGGGTTAG-3' minimal binding site, sequence specificity, and internal binding to multimeric sites. J. Biol. Chem. 2004, 279:13241-13248.
33. Lei M., Podell E.R., Cech T.R. Structure of human POT1 bound to telomeric single-stranded DNA provides a model for chromosome end-protection. Nat. Struct. Mol. Biol. 2004, 11:1223-1229.
34. Wang B., Mai Y.C., Li Y., Hou J.Q., Huang S.L., Ou T.M., Tan J.H., An L.K., Li D., Gu L.Q., Huang Z.S. Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur. J. Med. Chem. 2010, 45:1415-1423.
35. Peng D., Tan J.H., Chen S.B., Ou T.M., Gu L.Q., Huang Z.S. Bisaryldiketene derivatives: a new class of selective ligands for c-myc G-quadruplex DNA. Bioorg. Med. Chem. 2010, 18:8235-8242.
36. Reed J., Gunaratnam M., Beltran M., Reszka A.P., Vilar R., Neidle S. TRAP-LIG, a modified telomere repeat amplification protocol assay to quantitate telomerase inhibition by small molecules. Anal. Biochem. 2008, 380:99-105.
37. Sun D., Thompson B., Cathers B.E., Salazar M., Kerwin S.M., Trent J.O., Jenkins T.C., Neidle S., Hurley L.H. Inhibition of human telomerase by a G-quadruplex-interactive compound. J. Med. Chem. 1997, 40:2113-2116.
38. Mergny J.L., Helene C. G-quadruplex DNA: a target for drug design. Nat. Med. 1998, 4:1366-1367.
39. Mergny J.L., Mailliet P., Lavelle F., Riou J.F., Laoui A., Helene C. The development of telomerase inhibitors: the G-quartet approach. Anticancer Drug Des. 1999, 14:327-339.